| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $37.5M | +11.7% | +16.3% |
| SG&A Expense | $9.4M | +3.6% | +14.2% |
| Operating Income | -$46.9M | -10.0% | -15.9% |
| Net Income | -$40.7M | -12.6% | -19.2% |
| EPS (Basic) | -$0.39 | -14.7% | -8.3% |
| EPS (Diluted) | -$0.39 | -14.7% | -8.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $46.0M | +6.0% | +2.7% |
| Current Assets | $573.9M | -4.9% | +14.9% |
| Total Assets | $583.5M | -4.9% | +14.1% |
| Current Liabilities | $21.6M | +3.6% | +14.2% |
| Total Liabilities | $24.8M | +2.3% | +10.8% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$105.2M | — | — |
| Capital Expenditures | $183K | — | — |
| Investing Cash Flow | -$82.6M | — | — |
| Financing Cash Flow | $192.1M | — | — |
| Free Cash Flow | -$105.4M | — | — |
| $558.6M |
| -5.2% |
| +14.3% |